DRESDEN, Germany--(BUSINESS WIRE)--Oct. 25, 2005--Cenix BioScience GmbH (Dresden), the leading specialist in advanced RNA interference (RNAi)-based research services, today announced that following the success of a pilot project started in late 2004, it has entered into a new agreement with Schering AG to extend their target validation partnership.
